Medpace price target raised to $454 from $446 at Baird

Baird raised the firm’s price target on Medpace to $454 from $446 and keeps an Outperform rating on the shares. The firm said they posted an amazing quarter with a big profit beat again, big raise again, big BS/CF metrics, and industry-leading high-quality growth.